Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform for 68Ga-Labeled PSMA-Targeted Radioconjugates
International Journal of Molecular Sciences · 19.08.2026 · 27 (16) · 7426
DOI: 10.3390/ijms27167426 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.08.2026. Verfasst von Aleksandr S Lunev und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123182 Moscow, Russia. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Glutamate Carboxypeptidase II, Antigens, Surface, Radiopharmaceuticals. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Federal Medical-Biological Agency, M.V. Lomonosov Moscow State University Program of Development.
Abstract (Originalsprache)
Preclinical models play a critical role in the development of PSMA-targeted radiopharmaceuticals for prostate cancer. However, many existing models have practical limitations, including slow tumor growth, low engraftment rates, and restricted availability, and all human PSMA-positive lines are confined to immunodeficient hosts. We developed and characterized a novel PSMA-expressing transgenic cell line, CT26-PSMA, as a practical tool for preclinical screening of PSMA-targeting agents. The CT26-PSMA cell line was established by stable transfection of the murine colon carcinoma CT26 cell line with human PSMA using the Sleeping Beauty transposon system. PSMA expression was confirmed by RT-qPCR (reverse transcription quantitative polymerase chain reaction), flow cytometry, and radioligand saturation binding on intact cells. Two [68Ga]Ga-labeled radioconjugates—the well-established PSMA-617 and a newly synthesized conjugate (Conjugate-1)—were used to validate the functionality of the model through in vitro binding, uptake and internalization studies, and through ex vivo biodistribution in CT26-PSMA tumor-bearing athymic male nu/nu mice. The CT26-PSMA cell line demonstrated high and stable PSMA expression, with approximately 95% of cells expressing the biomarker and no measurable loss over 16 passages in antibiotic-free medium. Saturation binding gave a receptor density of ∼3.5 × 106 sites per cell, approximately four-fold higher than that of LNCaP cells (∼0.8 × 106), with dissociation constants that were indistinguishable between the two radioconjugates and between the two cell lines (Kd 9.0–11.6 nM). Subcutaneous tumors reached ~300 mm3 within 8–10 days of inoculation, with a take rate of 10/10 versus 1/10 for LNCaP (Fisher’s exact test, p = 1.2 × 10−4). Both radiotracers showed saturable, 2-PMPA-blockable binding and uptake in CT26-PSMA cells, confirming the functional activity of the recombinant receptor. Biodistribution studies revealed accumulation of both conjugates in CT26-PSMA tumors, with generally comparable tumor-to-background profiles. The CT26-PSMA cell line represents a robust, rapid, and reproducible platform for preclinical evaluation of PSMA-targeting radiopharmaceuticals, and its murine BALB/c origin permits engraftment in immunocompetent or minimally immunosuppressed hosts, whereas existing human PSMA-positive lines do not. It is intended as a screening platform rather than as a model of prostate cancer biology. The validation data obtained with [68Ga]Ga-labelled conjugates confirm the suitability of this cell line for future studies of PSMA-directed compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123182 Moscow, Russia.
- Faculty of Chemistry, Federal State Educational Institution of Higher Professional Education Lomonosov Moscow State University, 119991 Moscow, Russia.
- Department of Biochemistry, People's Friendship University of Russia Named After Patrice Lumumba (RUDN University), 117198 Moscow, Russia.
- A. Granov Russian Research Center for Radiology and Surgical Technologies, 197758 St. Petersburg, Russia.
ORCID-Profile: Kristina A Petrosova, Marat G Rakhimov, Anastasiia A Uspenskaia, Aleksey E Machulkin, Alexandra E Zakharkina
Förderung
- Russian Science Foundation
- Federal Medical-Biological Agency
- M.V. Lomonosov Moscow State University Program of Development
- Federal Medical-Biological Agency (FMBA) of Russia
Zitieren
APA
Lunev, A. S., Petrosova, K. A., Rakhimov, M. G., Uspenskaia, A. A., Machulkin, A. E., Malakhov, I. S., Shashkova, O. A., Samoilovich, M. P., Zakharkina, A. E., & Larenkov, A. A. (2026). Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform for 68Ga-Labeled PSMA-Targeted Radioconjugates. International Journal of Molecular Sciences, 27(16), 7426. https://doi.org/10.3390/ijms27167426
Vancouver
Lunev AS, Petrosova KA, Rakhimov MG, Uspenskaia AA, Machulkin AE, Malakhov IS, et al. Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform for 68Ga-Labeled PSMA-Targeted Radioconjugates. International Journal of Molecular Sciences. 2026;27(16):7426. doi:10.3390/ijms27167426
BibTeX
@article{Lunev2026,
author = {Lunev, Aleksandr S and Petrosova, Kristina A and Rakhimov, Marat G and Uspenskaia, Anastasiia A and Machulkin, Aleksey E and Malakhov, Ipatii S and Shashkova, Olga A and Samoilovich, Marina P and Zakharkina, Alexandra E and Larenkov, Anton A},
title = {Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform for 68Ga-Labeled PSMA-Targeted Radioconjugates},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7426},
doi = {10.3390/ijms27167426}
}
EUVIMED